Business Context and Reporting Period
This Form 8-K is a current report filed by ReShape Lifesciences Inc. (not Vyome Holdings, Inc.) on May 30, 2025. The registrant is incorporated in Delaware and its common stock trades on The Nasdaq Capital Market under the symbol RSLS. The report details the entry into a material definitive agreement regarding a new equity offering.
Key Financial Metrics and Transaction Details
The filing does not report standard financial performance metrics such as revenue, profit, cash flow, or debt levels. Instead, it outlines the terms of a new financing arrangement:
- Transaction Type: At-the-market (ATM) public offering of common stock.
- Maximum Offering Size: Up to $9,700,000 in aggregate gross proceeds.
- Sales Agent: Maxim Group LLC (exclusive sales agent).
- Compensation: 3.0% of gross proceeds paid to the sales agent.
- Legal Expenses: Reimbursement of counsel fees up to $50,000 plus $3,000 per due diligence update session.
Material Changes Versus Prior Period
This filing represents a new corporate action rather than a change in historical financial performance. The material change is the establishment of a new mechanism to raise capital via an ATM offering, which was not in place prior to May 30, 2025. The filing text does not provide comparative financial data against prior periods.
Guidance, Outlook, and Risks
Management Commentary and Outlook: The Company has no obligation to sell any shares and may suspend offers at any time. The offering will terminate upon the sale of shares totaling $9,700,000 or upon termination of the agreement by either party.
Risks and Contingencies:
- Dilution: The issuance of new shares will result in dilution to existing shareholders.
- Market Conditions: Sales are subject to market conditions and the sales agent's commercially reasonable efforts.
- Legal Liability: The Company has agreed to indemnify Maxim against certain liabilities, including those under the Securities Act.
Key Facts for Investor Verification
- Verify the current share price to assess the potential dilution impact of selling up to $9.7 million in shares.
- Confirm the Company's current cash position and liquidity needs to understand the urgency of this capital raise.
- Review the attached Equity Distribution Agreement (Exhibit 1.1) for specific termination rights and covenants.
- Note that the filing explicitly states it is not an offer to sell securities in jurisdictions where such an offer would be unlawful.